- Home
- Publications
- Publication Search
- Publication Details
Title
Experimental medication treatment approaches for depression
Authors
Keywords
-
Journal
Translational Psychiatry
Volume 7, Issue 3, Pages e1068
Publisher
Springer Nature
Online
2017-03-22
DOI
10.1038/tp.2017.33
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression
- (2016) C. K. Loo et al. ACTA PSYCHIATRICA SCANDINAVICA
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
- (2016) Jaskaran B. Singh et al. AMERICAN JOURNAL OF PSYCHIATRY
- Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial
- (2016) Maurizio Fava et al. AMERICAN JOURNAL OF PSYCHIATRY
- Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation
- (2016) Cristina Cusin et al. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
- KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS
- (2016) Chadi G. Abdallah et al. DEPRESSION AND ANXIETY
- Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants
- (2016) Suresh Durgam et al. JOURNAL OF CLINICAL PSYCHIATRY
- Erratum: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
- (2016) M Fava et al. MOLECULAR PSYCHIATRY
- A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression
- (2016) D R Goldsmith et al. MOLECULAR PSYCHIATRY
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites
- (2016) Panos Zanos et al. NATURE
- A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression
- (2016) Erica M. Richards et al. PSYCHOPHARMACOLOGY
- What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder
- (2016) Gerard Sanacora JAMA Psychiatry
- Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression
- (2016) Jorge A. Quiroz et al. JAMA Psychiatry
- Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study
- (2015) George I. Papakostas et al. AMERICAN JOURNAL OF PSYCHIATRY
- Ketamine as a promising prototype for a new generation of rapid-acting antidepressants
- (2015) Chadi G. Abdallah et al. Annals of the New York Academy of Sciences
- The Nature of Placebo Response in Clinical Studies of Major Depressive Disorder
- (2015) George I. Papakostas et al. JOURNAL OF CLINICAL PSYCHIATRY
- The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
- (2015) Paul E. Greenberg et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Augmentation of a Nicotinic Acetylcholine Receptor Partial Agonist in Depression
- (2015) Maurizio Fava et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent
- (2015) SHELDON PRESKORN et al. Journal of Psychiatric Practice
- Erratum: Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
- (2015) Gerard Sanacora et al. NEUROPSYCHOPHARMACOLOGY
- Association Between Placebo-Activated Neural Systems and Antidepressant Responses
- (2015) Marta Peciña et al. JAMA Psychiatry
- Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review
- (2015) Nicolas D. Iadarola et al. Therapeutic Advances in Chronic Disease
- Ketamine’s Antidepressant Efficacy is Extended for at Least Four Weeks in Subjects with a Family History of an Alcohol Use Disorder
- (2015) Mark J. Niciu et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
- (2014) Kyle A.B. Lapidus et al. BIOLOGICAL PSYCHIATRY
- P.2.f.027 The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study
- (2014) J.A. Quiroz et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine
- (2014) Dawn F. Ionescu et al. JOURNAL OF CLINICAL PSYCHIATRY
- Riluzole likely lacks antidepressant efficacy in ketamine non-responders
- (2014) Mark J. Niciu et al. JOURNAL OF PSYCHIATRIC RESEARCH
- A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
- (2014) David A. Mrazek et al. PSYCHIATRIC SERVICES
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial
- (2013) James W. Murrough et al. AMERICAN JOURNAL OF PSYCHIATRY
- Antidepressant Augmentation Using theN-Methyl-d-Aspartate Antagonist Memantine
- (2013) Eric G. Smith et al. JOURNAL OF CLINICAL PSYCHIATRY
- Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies
- (2013) Emiliangelo Ratti et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects
- (2013) G Sanacora et al. MOLECULAR PSYCHIATRY
- GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects
- (2013) Jeffrey Burgdorf et al. NEUROPSYCHOPHARMACOLOGY
- Development of a Computerized Adaptive Test for Depression
- (2012) Robert D. Gibbons et al. ARCHIVES OF GENERAL PSYCHIATRY
- A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression
- (2012) Carlos A. Zarate et al. BIOLOGICAL PSYCHIATRY
- Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression
- (2012) Xiaochen Zhao et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Correlation Between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Major Depressive Disorder
- (2012) Nadia Iovieno et al. JOURNAL OF CLINICAL PSYCHIATRY
- The Vasopressin V1bReceptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders
- (2012) Guy Griebel et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder
- (2012) Lobna Ibrahim et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study
- (2012) Lobna Ibrahim et al. NEUROPSYCHOPHARMACOLOGY
- Opioid receptors: distinct roles in mood disorders
- (2012) Pierre-Eric Lutz et al. TRENDS IN NEUROSCIENCES
- A pharmacokinetic PET study of NK1 receptor occupancy
- (2011) Stefano Zamuner et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder
- (2011) Emiliangelo Ratti et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical Trial
- (2010) Wayne C. Drevets et al. BIOLOGICAL PSYCHIATRY
- Is Pharma Running Out of Brainy Ideas?
- (2010) G. Miller SCIENCE
- Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials
- (2009) J. Craig Nelson et al. AMERICAN JOURNAL OF PSYCHIATRY
- Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
- (2009) Marije aan het Rot et al. BIOLOGICAL PSYCHIATRY
- Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
- (2009) Francisco Lopez-Munoz et al. CURRENT PHARMACEUTICAL DESIGN
- Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
- (2009) Sanjay J. Mathew et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Family History of Alcohol Dependence and Initial Antidepressant Response to an N -methyl-D-aspartate Antagonist
- (2008) Laura E. Phelps et al. BIOLOGICAL PSYCHIATRY
- Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD
- (2008) George I. Papakostas et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
- (2008) Sheldon H. Preskorn et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started